Sanofi-Aventis reports PhIII success for diabetes drug

Sanofi-Aventis has gained some fresh evidence to back lixisenatide, its late-stage GLP-1 therapy for Type 2 diabetes. Researchers say that the drug improved glycemic control in patients and reduced glucose in blood cells, making its Phase III study a success. The therapy was licensed from Zealand Pharma. "We are pleased with the top-line results from our first Phase III study of this novel, once-daily GLP-1 agonist and are looking forward to sharing the full results later in the year," said...